Targeting liver X receptors in inflammation

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 8, 2013, Pages 977-990

  Steffensen, Knut R ^a   Jakobsson, Tomas ^a   Gustafsson, Jan Åke ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b University of Houston   (United States)

Author keywords

Inflammation; Liver X receptor; Oxysterol receptor; Transrepression

Indexed keywords

22 HYDROXYCHOLESTEROL; 24 HYDROXYCHOLESTEROL; 25 EPOXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; GSK 2033; GSK 9772; GW 6340; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LXR 623; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; SR 9238; UNCLASSIFIED DRUG; WYE 672;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BONE METABOLISM; DERMATITIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; KIDNEY INJURY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; ORPHAN NUCLEAR RECEPTORS; SIGNAL TRANSDUCTION;

EID: 84880367617     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.806490     Document Type: Review

References (133)

1. Apfel R, Benbrook D, Lernhardt E, et al. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 1994;14:7025-35
2. Teboul M, Enmark E, Li Q, et al. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci USA 1995;92:2096-100
3. Janowski BA, Willy PJ, Devi TR, et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-31 (Pubitemid 26360651)
4. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997;272:3137-40 (Pubitemid 27066798)
5. Viennois E, Mouzat K, Dufour J, et al. Selective liver X receptor modulators (SLiMs): what use in human health? Mol Cell Endocrinol 2012;351:129-41
6. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-9
7. Collins JL, Fivush AM, Watson MA, et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 2002;45:1963-6 (Pubitemid 34477709)
8. Zuercher WJ, Buckholz RG, Campobasso N, et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem 2010;53:3412-16
9. Hu B, Unwalla RJ, Goljer I, et al. Identification of phenylsulfone- substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist. J Med Chem 2010;53:3296-304
10. Yasuda T, Grillot D, Billheimer JT. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2010;30:781-6
11. Hu B, Jetter J, Kaufman D, et al. Further modification on phenyl acetic acid based quinolines as liver X receptor modulators. Bioorg Med Chem 2007;15:3321-33 (Pubitemid 46529263)
12. Chao EY, Caravella JA, Watson MA, et al. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem 2008;51:5758-65
13. Griffett K, Solt LA, El-Gendy Bel D, et al. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol 2013;8:559-67
14. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-14 (Pubitemid 43326865)
15. Farnegardh M, Bonn T, Sun S, et al. The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J Biol Chem 2003;278:38821-8 (Pubitemid 37229066)
16. Svensson S, Ostberg T, Jacobsson M, et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. Embo J 2003;22:4625-33 (Pubitemid 37162899)
17. Wagner BL, Valledor AF, Shao G, et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 2003;23:5780-9 (Pubitemid 36951340)
18. Jakobsson T, Venteclef N, Toresson G, et al. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol Cell 2009;34:510-18
19. Boergesen M, Pedersen TA, Gross B, et al. Genome-wide profiling of LXR, RXR and PPARalpha in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol 2012;32:852-67
20. Pehkonen P, Welter-Stahl L, Diwo J, et al. Genome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages. BMC Genomics 2012;13:50
21. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010;38:576-89
22. Li X, Zhang S, Blander G, et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007;28:91-106 (Pubitemid 47531974)
23. Kim KH, Yoon JM, Choi AH, et al. Liver X receptor ligands suppress ubiquitination and degradation of LXRalpha by displacing BARD1/BRCA1. Mol Endocrinol 2009;23:466-74
24. Chen M, Bradley MN, Beaven SW, et al. Phosphorylation of the liver X receptors. FEBS Lett 2006;580:4835-41 (Pubitemid 44286840)
25. Torra IP, Ismaili N, Feig JE, et al. Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol Cell Biol 2008;28:2626-36 (Pubitemid 351542363)
26. Yamamoto T, Shimano H, Inoue N, et al. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 2007;282:11687-95 (Pubitemid 47100691)
27. Anthonisen EH, Berven L, Holm S, et al. Nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose. J Biol Chem 2010;285:1607-15
28. Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 2007;25:57-70 (Pubitemid 46049061)
29. Venteclef N, Jakobsson T, Steffensen KR, et al. Metabolic nuclear receptor signaling and the inflammatory acute phase response. Trends Endocrinol Metab 2011;22:333-43
30. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005;122:707-21 (Pubitemid 41242636)
31. Lee JH, Park SM, Kim OS, et al. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol Cell 2009;35:806-17
32. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nature reviews. Mol Cell Biol 2012;13:213-24
33. Jakobsson T, Treuter E, Gustafsson JA, et al. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012;33:394-404
34. Kang J, Rivest S. Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver X receptors. Endocr Rev 2012;33:715-46
35. Zhang L, Reue K, Fong LG, et al. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler Thromb Vasc Biol 2012;32:2541-6
36. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007;117:3900-8 (Pubitemid 350224099)
37. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007;117:2216-24 (Pubitemid 47219566)
38. Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;113:90-7 (Pubitemid 43958493)
39. Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000;14:2819-30
40. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 2007;117:2337-46 (Pubitemid 47219578)
41. Yasuda T, Grillot D, Billheimer JT, et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2010;30:781-6
42. Lo Sasso G, Murzilli S, Salvatore L, et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab 2010;12:187-93
43. Feig JE, Pineda-Torra I, Sanson M, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 2010;120:4415-24
44. Joseph SB, Bradley MN, Castrillo A, et al. LXR-Dependent Gene Expression Is Important for Macrophage Survival and the Innate Immune Response. Cell 2004;119:299-309 (Pubitemid 39360910)
45. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-19 (Pubitemid 36227724)
46. Valledor AF, Hsu LC, Ogawa S, et al. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci USA 2004;101:17813-18 (Pubitemid 40051969)
47. Pascual-Garcia M, Valledor AF. Biological roles of liver X receptors in immune cells. Arch Immunol Ther Exp (Warsz) 2012;60:235-49
48. A-Gonzalez N, Bensinger SJ, Hong C, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009;31:245-58
49. Hong C, Kidani Y, A-Gonzalez N, et al. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J Clin Invest 2012;122:337-47
50. Blaschke F, Takata Y, Caglayan E. A nuclear receptor corepressor- dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res 2006;99:e88-99 (Pubitemid 44949660)
51. Venteclef N, Jakobsson T, Ehrlund A, et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Gen Dev 2010;24:381-95
52. Birrell MA, Catley MC, Hardaker E, et al. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J Biol Chem 2007;282:31882-90 (Pubitemid 350106460)
53. Smoak K, Madenspacher J, Jeyaseelan S, et al. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J Immunol 2008;180:3305-12
54. Korf H, Vander Beken S, Romano M, et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J Clin Invest 2009;119:1626-37
55. Bruhn KW, Marathe C, Maretti-Mira AC, et al. LXR deficiency confers increased protection against visceral Leishmania infection in mice. PLoS Negl Trop Dis 2010;4:e886
56. Wang YY, Dahle MK, Steffensen KR, et al. Liver X receptor agonist GW3965 dose-dependently regulates LPSmediated liver injury and modulates post-transcriptional TNFalpha production and p38 MAPK activation in liver macrophages. Shock 2009;32:548-53
57. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012;51(Suppl 5):v3-11
58. Collins-Racie LA, Yang Z, Arai M, et al. Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis. Osteoarthritis Cartilage 2009;17:832-42
59. Li N, Rivera-Bermudez MA, Zhang M, et al. LXR modulation blocks prostaglandin E2 production and matrix degradation in cartilage and alleviates pain in a rat osteoarthritis model. Proc Natl Acad Sci USA 2010;107:3734-9
60. Park MC, Kwon YJ, Chung SJ, et al. Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology 2010;49:882-90
61. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-15 (Pubitemid 26363967)
62. Laragione T, Gulko PS. Liver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix metalloproteinase 2 activation, interleukin-6 and CXCL10. Mol Med 2012;18:1009-17
63. Yoon CH, Kwon YJ, Lee SW, et al. Activation of liver x receptors suppresses inflammatory gene expressions and transcriptional corepressor clearance in rheumatoid arthritis fibroblast like synoviocytes. J Clin Immunol 2013;33:190-9
64. Asquith D, Miller AM, Hueber AJ, et al. Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum 2009;60:2655-65
65. Asquith DL, Miller AM, Reilly J, et al. Simultaneous activation of the liver X receptors (LXRalpha and LXRbeta) drives murine collagen-induced arthritis disease pathology. Ann Rheum Dis 2011;70:2225-8
66. Asquith DL, Ballantine LE, Nijjar JS, et al. The liver X receptor pathway is highly upregulated in rheumatoid arthritis synovial macrophages and potentiates TLR-driven cytokine release. Ann Rheum Dis 2013; [Epub ahead of print]
67. Robertson KM, Norgard M, et al. Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. J Bone Miner Res 2006;21:1276-87 (Pubitemid 44128341)
68. Prawitt J, Beil FT, Marshall RP, et al. Short-term activation of liver X receptors inhibits osteoblasts but long-term activation does not have an impact on murine bone in vivo. Bone 2011;48:339-46
69. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40:251-64 (Pubitemid 46054562)
70. Remen KM, Henning P, Lerner UH, et al. Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclast differentiation in an LXRbeta-dependent mechanism. J Biol Chem 2011;286:33084-94
71. Kleyer A, Scholtysek C, Bottesch E, et al. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res 2012;27:2442-51
72. Robertson-Remen KM, Lerner UH, Gustafsson JA, et al. Activation of the liver X receptor-beta potently inhibits osteoclastogenesis from lipopolysaccharide-exposed bone marrow-derived macrophages. J Leukoc Biol 2013;93:71-82
73. Robertson-Remen KM, Gustafsson JA, Andersson G. The liver X receptor promotes macrophage differentiation and suppresses osteoclast formation in mouse RAW264.7 promyelocytic leukemia cells exposed to bacterial lipopolysaccharide. Biochem Biophys Res Commun 2013;430:375-80
74. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol 2009;201:309-20
75. Kiss E, Popovic Z, Bedke J, et al. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRalpha. Am J Pathol 2011;179:92-103
76. Kiss E, Kranzlin B, Wagenblabeta K, et al. Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors. Am J Pathol 2013;182:727-41
77. Tachibana H, Ogawa D, Matsushita Y, et al. Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 2012;23:1835-46
78. Albanesi C, Pastore S. Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs. Curr Drug Metab 2010;11:210-27
79. Komuves LG, Schmuth M, Fowler AJ, et al. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Investi Dermatol 2002;118:25-34 (Pubitemid 34107420)
80. Schmuth M, Elias PM, Hanley K, et al. The effect of LXR activators on AP-1 proteins in keratinocytes. J Investi Dermatol 2004;123:41-8 (Pubitemid 38833461)
81. Fowler AJ, Sheu MY, Schmuth M, et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Investi Dermatol 2003;120:246-55 (Pubitemid 36513075)
82. Kumar R, Parsad D, Kanwar A, et al. Altered levels of LXR-alpha: crucial implications in the pathogenesis of vitiligo. Exp Dermatol 2012;21:853-8
83. Lee CS, Park M, Han J, et al. Liver X receptor activation inhibits melanogenesis through the acceleration of ERK-mediated MITF degradation. J Invest Dermatol 2013;33:1063-71
84. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011;377:1019-31
85. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004;23:159-69 (Pubitemid 38980441)
86. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 2005;280:4079-88 (Pubitemid 40288571)
87. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007;104:10601-6 (Pubitemid 47185711)
88. Cui W, Sun Y, Wang Z, et al. Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice. Neuroscience 2012;210:200-10
89. Repa JJ, Li H, Frank-Cannon TC, et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 2007;27:14470-80
90. Terwel D, Steffensen KR, Verghese PB, et al. Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial abeta phagocytosis. J Neurosci 2011;31:7049-59
91. Gourraud PA, Harbo HF, Hauser SL, et al. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012;248:87-103
92. Saijo K, Crotti A, Glass CK. Nuclear receptors, inflammation, and neurodegenerative diseases. Adv Immunol 2010;106:21-59
93. Hindinger C, Hinton DR, Kirwin SJ, et al. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J Neurosci Res 2006;84:1225-34 (Pubitemid 44654446)
94. Xu J, Wagoner G, Douglas JC, et al. Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity. J Leukoc Biol 2009;86:401-9
95. Cui G, Qin X, Wu L, et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 2011;121:658-70
96. Bogie JF, Timmermans S, Huynh-Thu VA, et al. Myelin-derived lipids modulate macrophage activity by liver X receptor activation. PLoS One 2012;7:e44998
97. Sironi L, Mitro N, Cimino M, et al. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett 2008;582:3396-400
98. Morales JR, Ballesteros I, Deniz JM, et al. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008;118:1450-9
99. Namjoshi DR, Martin G, Donkin J, et al. The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E. PLoS One 2013;8:e53529
100. Cui X, Chopp M, Zacharek A, et al. The neurorestorative benefit of GW3965 treatment of stroke in mice. Stroke 2013;44:153-61
101. Steinman RM, Granelli-Piperno A, Pope M, et al. The interaction of immunodeficiency viruses with dendritic cells. Curr Top Microbiol Immunol 2003;276:1-30 (Pubitemid 36538345)
102. Hanley TM, Blay Puryear W, Gummuluru S, et al. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog 2010;6:e1000981
103. Morrow MP, Grant A, Mujawar Z, et al. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol Pharmacol 2010;78:215-25
104. Hanley TM, Viglianti GA. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J Virol 2011;85:10834-50
105. Dubrovsky L, Van Duyne R, Senina S, et al. Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection. Biochem Biophys Res Commun 2012;419:95-8
106. Jiang H, Badralmaa Y, Yang J, et al. Retinoic acid and liver X receptor agonist synergistically inhibit HIV infection in CD4+ T cells by up-regulating ABCA1-mediated cholesterol efflux. Lipids Health Dis 2012;11:69
107. Kim K, Kim KH, Kim HH, et al. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J 2008;416:219-30
108. Na TY, Shin YK, Roh KJ, et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009;49:1122-31
109. Lima-Cabello E, Garcia-Mediavilla MV, Miquilena-Colina ME, et al. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci 2011;120:239-50
110. Garcia-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, et al. Liver X receptor alpha-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Invest 2012;92:1191-202
111. Zeng J, Wu Y, Liao Q, et al. Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner. Antiviral Res 2012;95:245-56
112. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Research 2007;2007:95103
113. Kowluru RA, Kanwar M, Chan PS, et al. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch Ophthalmol 2008;126:1266-72
114. Hazra S, Rasheed A, Bhatwadekar A, et al. Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes. Diabetes 2012;61:3270-9
115. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96 (Pubitemid 46697910)
116. Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010;16:98-105
117. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-7
118. Hu X, Steffensen KR, Jiang ZY, et al. LXRbeta activation increases intestinal cholesterol absorption leading to an atherogenic lipoprotein profile. J Intern Med 2012;272:452-64
119. Zhang Y, Breevoort SR, Angdisen J. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest 2012;122:1688-99
120. Yang C, McDonald JG, Patel A, et al. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem 2006;281:27816-26 (Pubitemid 44414494)
121. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012;151:138-52
122. Theofilopoulos S, Wang Y, Kitambi SS, et al. Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol 2012;9:126-33
123. Quinet EM, Basso MD, Halpern AR, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 2009;50:2358-70
124. Katz A, Udata C, Ott E, et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009;49:643-9
125. Sacchetti P, Sousa KM, Hall AC, et al. Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. Cell Stem Cell 2009;5:409-19
126. Fan X, Kim HJ, Bouton D, et al. Expression of liver X receptor beta is essential for formation of superficial cortical layers and migration of later-born neurons. Proc Natl Acad Sci USA 2008;105:13445-50
127. Kim HJ, Fan X, Gabbi C, et al. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc Natl Acad Sci USA 2008;105:2094-9 (Pubitemid 351439470)
128. Dai YB, Tan XJ, Wu WF, et al. Liver X receptor beta protects dopaminergic neurons in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 2012;109:13112-17
129. Andersson S, Gustafsson N, Warner M, et al. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci USA 2005;102:3857-62 (Pubitemid 40354701)
130. Bigini P, Steffensen KR, Ferrario A, et al. Neuropathologic and biochemical changes during disease progression in liver X receptor beta-/-mice, a model of adult neuron disease. J Neuropathol Exp Neurol 2010;69:593-605
131. Freemantle E, Chen GG, Cruceanu C, et al. Analysis of oxysterols and cholesterol in prefrontal cortex of suicides. Int J Neuropsychopharmacol 2013; [Epub ahead of print]
132. Kotokorpi P, Ellis E, Parini P, et al. Physiological differences between human and rat primary hepatocytes in response to liver X receptor activation by 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyl oxy] phenylacetic acid hydrochloride (GW3965). Mol Pharmacol 2007;72:947-55 (Pubitemid 47481417)
133. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice. Nat Biotechnol 2007;25:903-10